KalVista Pharmaceuticals (KALV) Competitors $14.01 -0.80 (-5.40%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$13.94 -0.06 (-0.46%) As of 09/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALV vs. KYMR, RARE, TLX, NAMS, VKTX, XENE, AMRX, SRRK, IMVT, and MORShould you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include Kymera Therapeutics (KYMR), Ultragenyx Pharmaceutical (RARE), Telix Pharmaceuticals (TLX), NewAmsterdam Pharma (NAMS), Viking Therapeutics (VKTX), Xenon Pharmaceuticals (XENE), AMNEAL PHARMACEUTICALS (AMRX), Scholar Rock (SRRK), Immunovant (IMVT), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry. KalVista Pharmaceuticals vs. Its Competitors Kymera Therapeutics Ultragenyx Pharmaceutical Telix Pharmaceuticals NewAmsterdam Pharma Viking Therapeutics Xenon Pharmaceuticals AMNEAL PHARMACEUTICALS Scholar Rock Immunovant MorphoSys Kymera Therapeutics (NASDAQ:KYMR) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk. Is KYMR or KALV more profitable? KalVista Pharmaceuticals has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -616.03%. Kymera Therapeutics' return on equity of -31.60% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Kymera Therapeutics-616.03% -31.60% -27.12% KalVista Pharmaceuticals N/A -162.69%-88.61% Do analysts rate KYMR or KALV? Kymera Therapeutics currently has a consensus price target of $58.76, suggesting a potential upside of 25.06%. KalVista Pharmaceuticals has a consensus price target of $26.43, suggesting a potential upside of 88.64%. Given KalVista Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe KalVista Pharmaceuticals is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 15 Buy rating(s) 2 Strong Buy rating(s) 3.06KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Does the media favor KYMR or KALV? In the previous week, KalVista Pharmaceuticals had 17 more articles in the media than Kymera Therapeutics. MarketBeat recorded 24 mentions for KalVista Pharmaceuticals and 7 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.33 beat KalVista Pharmaceuticals' score of 0.57 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KalVista Pharmaceuticals 9 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings & valuation, KYMR or KALV? KalVista Pharmaceuticals has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKymera Therapeutics$44.71M75.14-$223.86M-$3.47-13.54KalVista PharmaceuticalsN/AN/A-$183.44M-$3.94-3.56 Which has more volatility and risk, KYMR or KALV? Kymera Therapeutics has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500. SummaryKymera Therapeutics beats KalVista Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KALV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALV vs. The Competition Export to ExcelMetricKalVista PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$745.53M$2.59B$5.84B$10.14BDividend YieldN/A56.52%5.68%4.60%P/E Ratio-3.5623.8575.4125.98Price / SalesN/A529.66515.81181.13Price / CashN/A171.1637.5660.44Price / Book7.305.3712.156.29Net Income-$183.44M$32.95M$3.29B$271.07M7 Day Performance-11.44%1.28%0.73%3.87%1 Month Performance8.19%5.61%4.99%5.49%1 Year Performance25.76%-1.67%62.53%25.86% KalVista Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALVKalVista Pharmaceuticals4.0191 of 5 stars$14.01-5.4%$26.43+88.6%+25.8%$745.53MN/A-3.56100Trending NewsEarnings ReportAnalyst ForecastInsider TradeHigh Trading VolumeKYMRKymera Therapeutics2.6867 of 5 stars$43.26-0.6%$58.76+35.8%+2.0%$3.11B$47.07M-12.47170Positive NewsRAREUltragenyx Pharmaceutical4.4639 of 5 stars$31.51-1.0%$81.50+158.6%-48.4%$3.07B$560.23M-5.701,294Positive NewsAnalyst ForecastTLXTelix Pharmaceuticals3.6681 of 5 stars$9.05-0.1%$22.33+146.8%N/A$3.07B$516.72M0.00N/ANews CoverageAnalyst ForecastGap DownNAMSNewAmsterdam Pharma3.361 of 5 stars$25.09-7.1%$41.55+65.6%+51.6%$3.04B$45.56M-15.494News CoveragePositive NewsInsider TradeHigh Trading VolumeVKTXViking Therapeutics4.2738 of 5 stars$25.48-5.6%$86.92+241.1%-62.8%$3.03BN/A-16.6520Positive NewsXENEXenon Pharmaceuticals2.4021 of 5 stars$38.19-2.6%$53.30+39.6%-11.3%$3.02B$9.43M-10.76210Positive NewsAMRXAMNEAL PHARMACEUTICALS2.747 of 5 stars$9.73+1.1%$11.60+19.2%+16.0%$3.02B$2.79B973.978,100News CoveragePositive NewsSRRKScholar Rock4.4731 of 5 stars$31.58+0.5%$45.75+44.9%+269.5%$3.02B$33.19M-10.85140News CoveragePositive NewsIMVTImmunovant2.462 of 5 stars$16.37-4.5%$33.60+105.3%-45.5%$2.99BN/A-5.74120MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730 Related Companies and Tools Related Companies KYMR Alternatives RARE Alternatives TLX Alternatives NAMS Alternatives VKTX Alternatives XENE Alternatives AMRX Alternatives SRRK Alternatives IMVT Alternatives MOR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KALV) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredExpert Alert: Massive Bubble Could Crash Your WealthOn July 4th, Trump signed the “One Big Beautiful Bill,” adding $3.4 trillion to the national debt — and pushin...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KALV Stock Alerts